Alkermes PLC Form 4 insider transactions

Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson, exercised stock options and sold ordinary shares, while also receiving new option and RSU awards, all under a pre-arranged 10b5-1 trading plan.

An Alkermes executive sold ordinary shares under a 10b5-1 plan while also receiving new stock options and restricted stock units.

Alkermes' VP of Finance, Samuel Joseph Parisi, reported the exercise of restricted stock units and a subsequent sale of shares for tax purposes.

Alkermes plc's SVP, Chief Commercial Officer, Christian Todd Nichols, reported the vesting of restricted stock units and subsequent sale of shares for tax purposes.

Alkermes' Chief Operating Officer, Blair C. Jackson, acquired shares through RSU vesting and sold a portion for tax obligations.

Alkermes plc's EVP R&D and Chief Medical Officer, Craig C. Hopkinson, reported the exercise of restricted stock units and a subsequent sale of ordinary shares.

Alkermes plc's EVP, CLO, David Joseph Gaffin, reported the acquisition of 6,866 ordinary shares and the disposition of 3,049 shares for tax purposes.

Alkermes plc's VP of Finance, Samuel Joseph Parisi, reported the vesting and exercise of restricted stock units and a subsequent sale of shares for tax purposes.

Alkermes SVP Christian Todd Nichols reported a pre-planned acquisition of 6,407 ordinary shares and a disposition of 2,845 shares for tax withholding purposes.

Alkermes plc's EVP and Chief Operating Officer, Blair Curtis Jackson, acquired 8,738 ordinary shares through a restricted stock unit award vesting and subsequently sold 3,880 shares to cover tax obligations.

Alkermes plc's EVP R&D and Chief Medical Officer, Craig C. Hopkinson, acquired ordinary shares through RSU vesting and subsequently sold a portion for tax obligations.

Alkermes plc. Executive Vice President and Chief Legal Officer, David Joseph Gaffin, exercised restricted stock units and subsequently sold a portion of the resulting ordinary shares for tax purposes.

Alkermes plc CEO Richard F. Pops acquired 149,580 ordinary shares through the vesting of performance-based restricted stock units, while also disposing of 62,230 shares for tax obligations.

Alkermes' Chief Commercial Officer, Christian Todd Nichols, increased his direct ownership of ordinary shares following the vesting of performance-based restricted stock units.

Alkermes plc's Chief Operating Officer, Blair C. Jackson, increased direct beneficial ownership of ordinary shares following the vesting of performance-based restricted stock units.

Alkermes plc's EVP R&D and Chief Medical Officer, Craig C. Hopkinson, acquired 25,352 ordinary shares through the vesting of performance-based restricted stock units.

Alkermes plc. EVP, CLO David Joseph Gaffin reported the vesting of performance-based restricted stock units and a subsequent sale of shares.

Alkermes EVP R&D and Chief Medical Officer, Craig C. Hopkinson, exercised stock options and sold a portion of his ordinary shares on February 2, 2026, under a pre-arranged 10b5-1 trading plan.

Alkermes plc Director Shane Cooke exercised stock options and subsequently sold 61,200 ordinary shares under a pre-arranged 10b5-1 trading plan.

Alkermes EVP R&D and Chief Medical Officer, Craig C. Hopkinson, filed a Form 4 detailing a future exercise of stock options and subsequent sale of 5,000 ordinary shares on January 8, 2026, under a pre-arranged 10b5-1 trading plan.

Alkermes plc's EVP R&D and Chief Medical Officer, Craig C. Hopkinson, sold 4,000 ordinary shares for $28 each under a pre-arranged 10b5-1 trading plan.

Alkermes' EVP of R&D and Chief Medical Officer, Craig C. Hopkinson, exercised stock options and subsequently sold 3,748 ordinary shares for a profit.

Alkermes plc's EVP R&D and Chief Medical Officer, Craig C. Hopkinson, has filed a Form 4 detailing a planned sale of 4,000 ordinary shares on December 1, 2025, under a Rule 10b5-1 trading plan.

Alkermes' EVP R&D and Chief Medical Officer, Craig C. Hopkinson, exercised stock options and subsequently sold a portion of his shares under a pre-arranged trading plan.

Craig C. Hopkinson, Alkermes plc's EVP R&D and Chief Medical Officer, executed a pre-arranged 10b5-1 plan, exercising stock options and subsequently selling ordinary shares.

Alkermes plc's SVP and Chief Financial Officer, Joshua Reed, was granted 158,743 employee stock options and 36,656 restricted stock units.

Alkermes plc's EVP and Chief Legal Officer, David Joseph Gaffin, exercised restricted stock units and sold a portion of the resulting shares to cover tax obligations.

Christian Todd Nichols, SVP and Chief Commercial Officer of Alkermes plc, has reported the sale of 6,667 ordinary shares of the company's stock across two transactions in early June 2025, executed under a pre-arranged 10b5-1 trading plan.

Alkermes plc Director Christopher I. Wright reported the acquisition of 3,301 ordinary shares through a restricted stock unit award vesting and the subsequent disposition of 793 shares for tax withholding purposes.

Alkermes plc. Director Cato T. Laurencin reported the exercise of restricted stock units and a subsequent sale of shares to cover tax obligations, as detailed in a recent SEC Form 4 filing.